If you have been watching Aurinia Pharmaceuticals lately, you are not alone. With the stock closing at $11.27 and boasting a hair-raising 59.2% gain over the past year, it is no wonder investors are ...
Title: Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the ENLIGHT-LN Registry Presenting Author: Mohammad Kamgar, M ...
ROCKVILLE, Md. & EDMONTON, Alberta - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) will present five posters with new data on its lupus nephritis medication LUPKYNIS (voclosporin) at two upcoming medical ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aurinia Pharmaceuticals ( (AUPH)) has ...
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.02 per share a year ago.
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback